Tyrosine Kinase/Adaptors
Tyrosine kinase and adaptor inhibitors are compounds that target tyrosine kinases and their associated adaptor proteins, which play pivotal roles in cell signaling, growth, and differentiation. These inhibitors are essential tools in cancer research, as many tyrosine kinases are involved in the signaling pathways that drive tumor growth and metastasis. By inhibiting tyrosine kinases, these compounds can block critical signaling cascades, offering potential therapeutic strategies for various cancers and other diseases involving abnormal cell signaling. At CymitQuimica, we provide a comprehensive range of high-quality tyrosine kinase and adaptor inhibitors to support your research in oncology, molecular biology, and targeted therapy development.
Subcategories of "Tyrosine Kinase/Adaptors"
- ALK(123 products)
- CSF-1R(42 products)
- EGFR(595 products)
- Ephrin Receptor(23 products)
- FLT(88 products)
- Fibroblast Growth Factor Receptor (FGFR)(176 products)
- HER(4 products)
- Hck(3 products)
- IGF-1R(102 products)
- PDGFR(126 products)
- PYK2(7 products)
- Src(81 products)
- TAM Receptor(33 products)
- Tie-2(20 products)
- Trk receptor(59 products)
- Tyrosine Kinases(25 products)
- VEGFR(252 products)
- c-Fms(111 products)
- c-Kit(113 products)
- c-Met/HGFR(134 products)
- c-RET(58 products)
Show 13 more subcategories
Found 1236 products of "Tyrosine Kinase/Adaptors"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
HER2-IN-8
CAS:HER2-IN-8 is an inhibitor of HER-2 that can be used in the study of cancer and inflammation-related diseases.Formula:C26H25F2N9O3Color and Shape:SolidMolecular weight:549.53EGFR-IN-135
EGFR-IN-135 (compound 3d) is an EGFR inhibitor with an IC50 value of 0.086 µM. It inhibits cell growth and arrests the cell cycle in the S phase in breast cancer cell lines.Formula:C12H14N4OS2Color and Shape:SolidMolecular weight:294.4DYRKs-IN-1
CAS:<p>DYRKs-IN-1 has antitumor activity.</p>Formula:C30H30ClN7O4Purity:98%Color and Shape:SolidMolecular weight:588.06PET-cGMP
CAS:<p>PET-cGMP is an analogue of cyclic guanosine monophosphate and functions as a potent, selective agonist for PKGI. It exhibits an EC50 of 3.8 nM for PKGIβ and 193 nM for PKGII.</p>Formula:C18H16N5O7PColor and Shape:SolidMolecular weight:445.323EGFR-IN-24
EGFR-IN-24 is a potent inhibitor of EGFR and inhibits EGFR (del19/T790M/C797S) and EGFR (L858R/T790M/C797S).Formula:C30H35FN6O3Color and Shape:SolidMolecular weight:546.64JBJ-02-112-05
CAS:JBJ-02-112-05 is a potent, mutant-selective, allosteric and orally active inhibitor of EGFR with an IC 50 of 15 nM for EGFR L858R/T790M [1].Formula:C27H20N4O2SPurity:98%Color and Shape:SolidMolecular weight:464.54AZ8010
CAS:AZ8010 (AZ12908010) serves as an effective inhibitor of FGFR1-3 and exhibits antiproliferative properties, making it useful for cancer research.Formula:C27H34N4O3Color and Shape:SolidMolecular weight:462.58TrkA-IN-7
CAS:<p>TrkA-IN-7 (Compound 4) is an inhibitor of tropomyosin receptor kinase A (TrkA), with a Kd value of 40 μM.</p>Formula:C16H13N3O3Color and Shape:SolidMolecular weight:295.293KRC-00715
CAS:<p>KRC-00715 is an orally effective inhibitor of c-Met, exhibiting high selectivity with an IC50 of 9.0 nM. This compound specifically inhibits the growth of gastric cancer cell lines with high c-Met expression by inducing G1/S phase block, and reduces the activity of downstream signals, including Akt, Erk, and c-Met itself. In the gastric cancer cell line Hs746T, KRC-00715 demonstrates cytotoxicity with an IC50 of 39 nM and selectively inhibits the proliferation of cell lines that overexpress c-Met. Additionally, KRC-00715 decreases tumor size in Hs746T xenograft mouse models.</p>Formula:C25H25F3N8O3Color and Shape:SolidMolecular weight:542.51EGFR/VEGFR2-IN-2
<p>EGFR/VEGFR2-IN-2 (compound 4b) serves as a dual inhibitor of VEGFR-2 and EGFR.</p>Formula:C24H15FO3Color and Shape:SolidMolecular weight:370.37JBJ-09-063
CAS:JBJ-09-063: EGFR inhibitor, IC50s 0.147-0.396 nM for various mutants; hinders EGFR/Akt/ERK1/2 phosphorylation; targets TKI-sensitive/resistant lung cancer.Formula:C31H29FN4O3SColor and Shape:SolidMolecular weight:556.65Enbezotinib
CAS:Enbezotinib is an inhibitor of RET autophosphorylation and can be used in cancer research.Formula:C21H21FN6O3Purity:99.84%Color and Shape:SolidMolecular weight:424.43AZ12601011
CAS:<p>AZ12601011 is a TGFBR1 kinase inhibitor that inhibits the growth of breast tumors.</p>Formula:C19H15N5Purity:98.81%Color and Shape:SolidMolecular weight:313.36Vecabrutinib
CAS:<p>Vecabrutinib (SNS-062) is a potent and noncovalent BTK and ITK inhibitor (Kd: 0.3 nM and 2.2 nM, respectively). Vecabrutinib displays an IC50 of 24 nM for ITK.</p>Formula:C22H24ClF4N7O2Purity:99.74%Color and Shape:SolidMolecular weight:529.92Zotizalkib
CAS:TPX-0131: potent, selective, CNS-ready, oral ALK inhibitor (WT IC50: 1.4nM, G1202R/L1196M IC50: 0.3nM) with robust antitumor effects.Formula:C21H20F3N5O3Purity:98.7%Color and Shape:SolidMolecular weight:447.41AGL-2263
CAS:AGL-2263 is a blocker of insulin receptor (IR)Formula:C17H10N2O5Color and Shape:SolidMolecular weight:322.27EGFR-IN-7
CAS:<p>EGFR-IN-7 (TQB3804) is a selective and potent EGFR kinase inhibitor.</p>Formula:C32H41BrN9O2PPurity:95.32% - 99.64%Color and Shape:SolidMolecular weight:694.6Nimotuzumab (powder)
CAS:<p>Nimotuzumab (powder) is a humanized IgG1 monoclonal antibody that specifically targets the epidermal growth factor receptor (EGFR), possessing a dissociation constant (KD) of 0.21 nM. It blocks the binding to its ligand by targeting the extracellular domain of EGFR. Nimotuzumab exhibits strong antitumor activity by inducing both antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), exerting cytolytic effects on target tumors.</p>Color and Shape:LiquidTyrosine kinase inhibitor
CAS:Tyrosine kinase inhibitor is a tyrosine kinase inhibitor used in combination with fragmenting aromatic nitrogen compounds as antiproliferative agents.Formula:C31H31FN6O5Purity:98%Color and Shape:SolidMolecular weight:586.61HMBD-001
<p>HMBD-001 is a humanized IgG1 monoclonal antibody inhibitor that targets HER3. By inhibiting the dimerization of HER3, HMBD-001 suppresses the growth and proliferation of tumor cells. It holds potential for research in cancer treatments, specifically for pancreatic cancer and non-small cell lung cancer.</p>Color and Shape:Odour LiquidTLC9995-0188
CAS:Tyrosine-protein kinase ABL, IC50: 1500 nMFormula:C16H15N5Color and Shape:Yellow SolidMolecular weight:277.331Olmutinib
CAS:Olmutinib (BI1482694) is a Novel Epidermal Growth Factor Receptor Tyrosine Kinase InhibitorFormula:C26H26N6O2SPurity:99.14%Color and Shape:SolidMolecular weight:486.59Duligotuzumab
CAS:<p>Duligotuzumab (MEHD-7945A) is a bispecific humanised IgG-κ monoclonal antibody targeting HER3 and EGFR, solid tumours, head and neck cancer,colorectal cancer.</p>Purity:95%Color and Shape:LiquidRef: TM-T80604
Discontinued productEGFR-IN-82
CAS:<p>EGFR-IN-82 (Compound 8a) is a potent, orally active inhibitor of EGFR, exhibiting IC50 values of 0.09 nM for EGFR L858R/T790M/C797S and 0.06 nM for EGFR Del19/</p>Formula:C32H41BrN9O2PPurity:98%Color and Shape:SolidMolecular weight:694.6FGFR1 inhibitor-10
CAS:<p>FGFR1 inhibitor-10 (Compound 4i), with an IC50 of 28 nM, effectively inhibits FGFR1 phosphorylation.</p>Formula:C26H30F3N7O2SPurity:98%Color and Shape:SolidMolecular weight:561.62Trk-IN-4
CAS:Trk-IN-4 (PF-6683324) is a potent pan-Trk inhibitor and antinociceptive. It is also a selective type II PTK6 inhibitor antitumor.Formula:C24H23F4N5O4Purity:98.13%Color and Shape:SolidMolecular weight:521.46BTK-IN-25
CAS:<p>BTK-IN-25 (compound 71) is a potent BTK inhibitor, demonstrating an IC50 of 0.77 nM against BTK(C481S) and achieving an IC50 of 1 nM in DOHH2 cells [1].</p>Formula:C28H27F2N3O5Purity:98%Color and Shape:SolidMolecular weight:523.53JDB175
CAS:<p>JDB175, a selective BTK inhibitor with oral bioavailability, demonstrates excellent penetration through the blood-brain barrier.</p>Formula:C26H21F3N4O2Purity:98%Color and Shape:SolidMolecular weight:478.47Canlitinib
CAS:<p>Canlitinib, a tyrosine kinase inhibitor, holds potential for cancer research.</p>Formula:C33H31F2N3O7Purity:98%Color and Shape:SolidMolecular weight:619.61APG-2449
CAS:<p>APG-2449 is an orally active inhibitor targeting ALK, ROS1, and FAK, demonstrating antitumor efficacy in mouse models of non-small cell lung cancer (NSCLC) [1].</p>Formula:C33H42ClN5O4SPurity:98%Color and Shape:SolidMolecular weight:640.24BTK-IN-27
CAS:<p>BTK-IN-27 (example 8), a potent BTK inhibitor with an IC50 of 0.2 nM, demonstrates anti-proliferative effects in TMD8 cells with an IC50 of less than 5 nM.</p>Formula:C31H35N7O2Purity:98%Color and Shape:SolidMolecular weight:537.66YK-029A
CAS:<p>YK-029A, an orally active EGFR mutant inhibitor, targets both EGFR T790M and EGFRex20ins mutations.</p>Formula:C27H32N8O2Purity:98%Color and Shape:SolidMolecular weight:500.6TrkB-IN-1
CAS:<p>TrkB-IN-1 is a potent, orally active agonist of the TrkB receptor, with favorable pharmacokinetic (PK) properties.</p>Formula:C19H16N2O6Purity:98%Color and Shape:SolidMolecular weight:368.34Syk-IN-8
CAS:<p>Syk-IN-8 (compound 19q) functions as a Syk inhibitor with demonstrated antiproliferative effects on a variety of hematological tumor cells.</p>Formula:C23H26N10Purity:98%Color and Shape:SolidMolecular weight:442.52EGFR-IN-122
CAS:<p>EGFR-IN-122 (compound Yfq07) serves as a potent inhibitor of EGFR. It effectively inhibits the proliferation of PC-9GR and HCC827GR cells.</p>Formula:C19H20N4O3Color and Shape:SolidMolecular weight:352.39Ref: TM-T200157
Discontinued productEGFR-IN-123
CAS:<p>EGFR-IN-123 (compound D06) is an effective EGFR inhibitor. It exhibits inhibitory activity against several cell lines including PC-9G, A549, A431, and HCT116, with IC50 values of 0.74, 1.36, 1.20, and 2.53 μM respectively.</p>Formula:C24H27F3N6OColor and Shape:SolidMolecular weight:472.51Ref: TM-T200485
Discontinued product
